This investigation examined several dimensions of personality functioning in a longitudinal sample of females. These data are part of an existing project evaluating female development across 3 different time points starting in adolescence and transitioning into adulthood. Subjects were categorized into a clinical group (females with a high degree of psychiatric comorbidity) and a normal control group. All participants were initially recruited when they were between 14-18 years of age, and were followed up twice when they were 19-23, and 24-28. In an attempt to explore possible heterogeneity in personality trait development, the research is presented as three separate studies examining the following: (1) fluctuations in mean-level and rank order stability estimates across time; (2) the validity of established personality trends relative to their association with antisocial behavior; and (3) mechanisms that may contribute to personality trait consistency across development such as neighborhood context. This is the first study to investigate personality functioning across time in females who are disturbed in multiple areas of social and psychological functioning. Results highlight the importance of considering distinct subgroups of the general population when exploring developmental trends in personality.

A paralisia cerebral é definida como uma alteração permanente do desenvolvimento da postura e movimento, causando limitações nas atividades, que são atribuídas a um distúrbio não progressivo que ocorre precocemente no encéfalo em desenvolvimento. A presença de comorbidades psiquiátricas traz piora funcional e na qualidade de vida dessas crianças e seu reconhecimento e tratamento deveriam fazer parte da rotina de centros de reabilitação. Este projeto tem como objetivo estudar as comorbidades psiquiátricas na paralisia cerebral. Foram avaliados 550 indivíduos com diagnóstico de paralisia cerebral, procedentes de um centro terciário de reabilitação física. A comorbidade psiquiátrica mais frequentemente observada foi a deficiência intelectual. Outras comorbidades psiquiátricas frequentes foram os transtornos ansiosos, transtornos do comportamento, transtorno do déficit de atenção e hiperatividade, transtorno do espectro autista e depressão. Embora não fosse o objetivo deste trabalho estudar a ocorrência de epilepsia nessa população, observamos que 43,2% dos nossos pacientes apresentaram essa associação. A presença de transtornos do espectro do autismo foi significativamente maior nos pacientes com epilepsia. A presença de um transtorno psiquiátrico impactou significativamente a percepção da funcionalidade das crianças com paralisia cerebral. Pensar na reabilitação desses sujeitos é levar em conta a presença de transtornos psiquiátricos. A pesquisa ativa de comorbidades deve ser prática rotineira dentro de centros de reabilitação terciários. Pensar em reabilitação do paciente com paralisia cerebral deve extrapolar os objetivos físicos e olhar com a mesma atenção para os aspectos emocionais, comportamentais, acadêmicos e sociais / Cerebral palsy is defined as a permanent change of posture and movement development, causing limitations in activities that are assigned to a non-progressive disorder that occurs early in the developing brain. The presence of psychiatric comorbidity brings functional deterioration and worsens quality of life of these children and their recognition and treatment should be part of routine of rehabilitation centers. This project aims to study psychiatric comorbidities in cerebral palsy. We evaluated 550 individuals diagnosed with cerebral palsy coming from a tertiary physical rehabilitation center. The most frequent psychiatric comorbidity was intellectual disability. Other frequent psychiatric comorbidities were anxiety disorders, behavioral disorders, attention deficit hyperactivity disorder, autism spectrum disorder and depression. Although it was not the objective of this work to study the occurrence of epilepsy in this population, we observed that 43.2% of our patients had this situation. The presence of autism spectrum disorders was significantly higher in patients with epilepsy. The presence of a psychiatric disorder significantly impacted the functionality of children with cerebral palsy. Thinking about the rehabilitation of these subjects is to take in account the presence of psychiatric disorders. The active search of comorbidities should be a routine practice in tertiary rehabilitation centers. Thinking about the rehabilitation of patients with cerebral palsy should extrapolate the physical goals and look with the same attention to the emotional, behavioral, academic and social aspects

A paralisia cerebral é definida como uma alteração permanente do desenvolvimento da postura e movimento, causando limitações nas atividades, que são atribuídas a um distúrbio não progressivo que ocorre precocemente no encéfalo em desenvolvimento. A presença de comorbidades psiquiátricas traz piora funcional e na qualidade de vida dessas crianças e seu reconhecimento e tratamento deveriam fazer parte da rotina de centros de reabilitação. Este projeto tem como objetivo estudar as comorbidades psiquiátricas na paralisia cerebral. Foram avaliados 550 indivíduos com diagnóstico de paralisia cerebral, procedentes de um centro terciário de reabilitação física. A comorbidade psiquiátrica mais frequentemente observada foi a deficiência intelectual. Outras comorbidades psiquiátricas frequentes foram os transtornos ansiosos, transtornos do comportamento, transtorno do déficit de atenção e hiperatividade, transtorno do espectro autista e depressão. Embora não fosse o objetivo deste trabalho estudar a ocorrência de epilepsia nessa população, observamos que 43,2% dos nossos pacientes apresentaram essa associação. A presença de transtornos do espectro do autismo foi significativamente maior nos pacientes com epilepsia. A presença de um transtorno psiquiátrico impactou significativamente a percepção da funcionalidade das crianças com paralisia cerebral. Pensar na reabilitação desses sujeitos é levar em conta a presença de transtornos psiquiátricos. A pesquisa ativa de comorbidades deve ser prática rotineira dentro de centros de reabilitação terciários. Pensar em reabilitação do paciente com paralisia cerebral deve extrapolar os objetivos físicos e olhar com a mesma atenção para os aspectos emocionais, comportamentais, acadêmicos e sociais / Cerebral palsy is defined as a permanent change of posture and movement development, causing limitations in activities that are assigned to a non-progressive disorder that occurs early in the developing brain. The presence of psychiatric comorbidity brings functional deterioration and worsens quality of life of these children and their recognition and treatment should be part of routine of rehabilitation centers. This project aims to study psychiatric comorbidities in cerebral palsy. We evaluated 550 individuals diagnosed with cerebral palsy coming from a tertiary physical rehabilitation center. The most frequent psychiatric comorbidity was intellectual disability. Other frequent psychiatric comorbidities were anxiety disorders, behavioral disorders, attention deficit hyperactivity disorder, autism spectrum disorder and depression. Although it was not the objective of this work to study the occurrence of epilepsy in this population, we observed that 43.2% of our patients had this situation. The presence of autism spectrum disorders was significantly higher in patients with epilepsy. The presence of a psychiatric disorder significantly impacted the functionality of children with cerebral palsy. Thinking about the rehabilitation of these subjects is to take in account the presence of psychiatric disorders. The active search of comorbidities should be a routine practice in tertiary rehabilitation centers. Thinking about the rehabilitation of patients with cerebral palsy should extrapolate the physical goals and look with the same attention to the emotional, behavioral, academic and social aspects

No description available.

In 2023, medication for opioid use disorder (MOUD), including methadone and buprenorphine, remains the most effective intervention for preventing overdose death among people who consume opioids. Yet, among those seeking treatment for opioid use disorder (OUD), there are disparities in access, quality of care, and treatment outcomes. Those disparities are related to attributes of people who use opioids, the circumstances of use, the nature of opioid use as a disease, and the design of services to treat the disease. The complex relationships between these attributes are not well articulated or understood. Health services research recognizes the biopsychosocial nature of the health conditions but research to improve treatment for OUD calls for a comprehensive, integrative, transdisciplinary approach. This dissertation presents such an approach by focusing on the biological and psychosocial implications of trauma and traumatic stress disorders in the etiology, presentation, and treatment of OUD. Aim 1 was to leverage a preclinical animal model in neuroscience to investigate how a fear memory cue may trigger recurrence of drug-seeking. Aim 2 was to examine how primary care clinicians incorporate principles of Trauma-Informed Care into OUD treatment based on qualitative interview accounts of their practices. Aim 3 was to leverage a longitudinal retrospective analysis of linked medical records and claims data to estimate the effect of post-traumatic stress disorder (PTSD) diagnosis on health services utilization and explores effect moderation by race and gender. The findings from the three studies inform each other, and the dissertation helps to clarify the significance of trauma in effectively and equitably serving people with OUD. Theoretically, the dissertation incorporates the tenets of Nancy Krieger’s Ecosocial Theory in its explication of OUD treatment. Ecosocial theory builds on the biopsychosocial approach in its inclusion of societal arrangements of power and structural oppression as shaping the pathways of embodiment. Many people with OUD incorporate lived experience of trauma. Utilization of formal OUD treatment settings can shape pathways of embodiment and may be yet another adverse exposure. The socially produced determinants of traumatic stress disorders and associated OUD should encourage health scientists to think critically and systematically about the connections between our biological, social, and psychological existence to be able to effectively respond to OUD as a complex biopsychosocial phenomenon. / 2025-08-23T00:00:00Z

No description available.

Introdução: A esquizofrenia é um dos principais transtornos mentais e promove distúrbios comportamentais e cognitivos. Apesar do grande impacto social, pouco se conhece sobre a patofisiologia e etiologia da esquizofrenia. Pacientes com desordens psicóticas têm aumentado risco de desenvolver epilepsia, e pacientes com epilepsia do lobo temporal tem alta frequência de psicoses. A utilização de modelos experimentais animais de esquizofrenia e epilepsia pode ajudar a entender a neurobiologia dessas doenças e ter papel importante no desenvolvimento de novas estratégias terapêuticas. As interações complexas das crises epilépticas e quadros psicóticos tem sido aos poucos desvendadas. O óxido nítrico (NO) é um importante modulador da neurotransmissão e doadores de NO como o nitroprussiato de sódio (NPS) tem efeitos promissores em pacientes com esquizofrenia. Em modelos animais de epilepsia, NO pode ter efeito pró ou anticonvulsivante, sugerindo que o uso de NPS em pacientes com epilepsia e psicose pode não ser tão simples. Objetivos: Desenvolver um modelo animal de epilepsia e psicose comórbida, e compará-lo do ponto de vista comportamental e neuropatológico com modelos animais puros de epilepsia e esquizofrenia. Além disso, verificar a possível modulação desencadeada pelo tratamento com NPS nos modelos citados. Metodologia: Ratos Wistar machos (260-300g) foram divididos em grupos controle (SAL+SAL), epilepsia puro (PILO+SAL), esquizofrenia (SAL+QUET), epilepsia e psicose comórbida (PILO+QUET) e suas versões tratadas com NPS (SAL+SAL+NPS, PILO+SAL+NPS, SAL+QUET+NPS e PILO+QUET+NPS). Esses animais foram avaliados em diferentes aspectos comportamentais (campo aberto, teste de inibição pré- pulso, memória de reconhecimento de objeto e memória de trabalho), e filmados ao longo de 71 dias para o monitoramento de crises epilépticas espontâneas recorrentes. Também foram avaliadas a perda neuronal e a expressão de nNOS em diferentes regiões cerebrais. Resultados: NPS reduziu a frequência de crises nos animais com epilepsia e psicose comórbida quando comparados a animais não tratados. NPS também teve efeito ansiolítico no modelo animal de epilepsia com e sem psicose, e diminuiu os correlatos comportamentais de sintomas positivos dos animais no modelo de psicose e no de epilepsia + psicose, além de reverter o prejuízo no filtro sensório motor nos animais que receberam pilocarpina e quetamina. No reconhecimento de objeto o modelo de epilepsia e epilepsia+psicose o tratamento com NPS não interferiu no desempenho de memória de curto prazo, porém NPS melhorou a memória de longo prazo no modelo de psicose. NPS preservou regiões como o córtex entorrinal e subiculum nos animais epilépticos, mas a camada granular e córtex pré-límbico revelaram perda significativa nos animais controles. Alta expressão de nNOS em diferentes regiões cerebrais foram visualizadas nos animais com epilepsia, com destaque para aqueles que receberam tratamento com NPS. Conclusão: O tratamento com NPS foi efetivo na amenização de sintomas correlatos comportamentais de psicose no modelo puro de esquizofrenia e no comórbido VIII com epilepsia. Além disso, não exacerbou crises e contribuiu para diminuição delas nos animais do modelo de epilepsia e psicose, que apresentou grandes similaridades com o que é encontrado em casos clínicos. Nossos resultados sugerem que o uso do NPS pode ter resultados na melhoria dos sintomas da psicose interictal humana, assim como já observado para a esquizofrenia. / Introdution: Schizophrenia is a major mental disorder that affects 1% of young adults and has a great impact on quality of life, behavior, and cognition. Despite the high social burden, little is known about the pathophysiology and etiology of schizophrenia. Patients with psychotic disorders have increased risk of developing epilepsy, and patients with temporal lobe epilepsy have a high frequency of psychoses. The use of experimental animal models of epilepsy and schizophrenia may help to better understand the neurobiology of these diseases and play an important role in the development of potential new therapeutic strategies. The complex interactions of seizures and psychotic symptoms are being unveiled. Nitric oxide (NO) is an important modulator of neurotransmission and NO donors such as sodium nitroprusside (SNP) have shown promising effects in schizophrenic patients. In animal models of epilepsy, NO may exert pro- or anticonvulsant effects, suggesting that the use of SNP in patients with epilepsy and psychosis may not be so straightforward. Objectives: To develop an animal model of epilepsy and comorbid psychosis, and compare it from the behavioral and neuropathological point of view with pure animal models of epilepsy and schizophrenia. It was hoped, to verify the possible modulation triggered by the treatment with SNP. Metodology: Males Wistar rats weighing 260-300g were divided in controls group (SAL+SAL), pure epilepsy (PILO+SAL), schizophrenia (SAL+QUET), comorbid psychosis (PILO+KET) and their versions treated with SNP (SAL+SAL+SNP, PILO+SAL+SNP, SAL+KET+SNP and PILO+KET+SNP). These animals were evaluated in a variety of behavioral tests (open field, prepulse inhibition startle reflex, object recognition and working memory), and were filmed over 71 days to monitor spontaneous recurrent seizures. We also evaluated neuronal loss and nNOS expression in different brain regions. Results: SNP reduced seizure frequency in animals with epilepsy and psychosis when compared to those not treated with SNP. SNP also showed anxiolytic effects in the animal model of epilepsy with or without psychosis, decreased behavioral correlates of positive symptoms in the animal model of epilepsy + psychosis, and prevented sensorimotor gating deficits in epilepsy + psychosis IX model, The object recognition test showed that in epilepsy and epilepsy + psychosis models the treatment with SNP did not interfere with short-term memory performance, but SNP improved long-term memory in the psychosis model. SNP preserved brain regions like entorhinal cortex and subiculum in epileptic animals, but the granular layer and prelimbic cortex revealed significant loss in controls animals. High expression of NOS in same brain regions was observed in the animal model of epilepsy, especially in the animals receiving SNP. Conclusion: Treatment with SNP was effective in ameliorating symptoms of behavioral correlates of psychosis in the pure model of schizophrenia and the model comorbid with epilepsy. Moreover, SNP did not exacerbate seizures and reduced seizure frequency in the animal model of epilepsy + psychosis, which showed striking similarities to clinical cases. Our results suggest that the use of SNP could ameliorate symptoms of human interictal psychosis, such as those observed in schizophrenia.

Die Organtransplantation hat sich in den letzten 20 Jahren zu einem Standardverfahren in der Therapie schwerer, anders nicht mehr behandelbarer Organerkrankungen entwickelt. In Deutschland werden jährlich etwa 3000 Transplantationen durchgeführt. Über 13 000 Menschen stehen auf der Warteliste für einen solchen Eingriff. Sowohl die Wartezeit als auch die verschiedenen Phasen nach dem Eingriff fordern erhebliche psychische Anpassungsleistungen von Patienten und Angehörigen, was häufig zu psychischen Störungen führt. Das Transplantationsgesetz von 1997 fordert daher ausdrücklich eine psychosomatische Mitbetreuung in den Transplantationszentren. Trotz dieses Therapiebedarfs fehlt es bisher an empirisch gesicherten therapeutischen Strategien. In der Transplantationsmedizin ist ein methodenübergreifender Betreuungsansatz sinnvoll. Kognitiv-verhaltenstherapeutische Therapieelemente scheinen aufgrund ihres pragmatischen und lösungsorientierten Ansatzes für diese Patientengruppe besonders geeignet. Ziel dieses Artikels ist es, auf Basis klinischer Erfahrungen und der wissenschaftlichen Literatur eine Übersicht über die unterschiedlichen Phasen der Transplantation solider Organe, ihre spezifischen Belastungen und therapeutische Strategien für Patienten und ihre Angehörigen zu geben. Der Bedarf an empirischer Forschung auf diesem Gebiet, gerade was die Wirksamkeit verhaltensmedizinischer Interventionen angeht, wird deutlich. / About 3,000 patients per year receive a transplant in Germany and some 13,000 patients are on waiting lists. Waiting period and the different stages of recovery demand special coping strategies from patients and their families. Psychological disorders are frequent before and after the transplantation and psychological risk factors are relevant for the outcome of the transplantation. Therefore special psychosomatic care for patients and their families is necessary. However, evidence based knowledge on appropriate therapeutic interventions is still scarce. In transplantation medicine, an overall approach is reasonable. Cognitive-behavioral aspects seem to be especially promising. The article describes strategies and techniques for the psychosomatic assessment of patients before transplantation and psychotherapeutic interventions for patients and their families before and after solid organ transplantation. More research on the effects of psychotherapeutic interventions in this field is necessary. / Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

Introduction: Eating disorders are serious psychiatric disorders that often require specialized care. Associated psychiatric comorbidity is frequent, with the most common comorbid conditions being anxiety and mood disorders. Eriksbergsgården in Örebro is one of Sweden’s specialized eating disorder treatment units.Aim: Primary aims were to describe clinical characteristics of the adult patient group at Eriksbergsgården and to evaluate treatment outcome and patient satisfaction at the one-year follow-up. An additional aim was to examine if factors such as psychiatric comorbidity affected treatment outcome.Methods: This study used data from Riksät and Stepwise, two large-scale Swedish registers for eating disorder treatment. Data for this study was registered into Stepwise and Riksät at Eriksbergsgården between August 2010 and December 2017 and 489 adult patients of both genders constituted the study group. Patient characteristics and DSM-IV axis I psychiatric comorbidity were assessed at the initial evaluation. At the one-year follow-up, treatment outcome and patient satisfaction were evaluated.Results: The most common diagnoses in this patient material were eating disorder not otherwise specified, 56.6 %, followed by bulimia nervosa, 26.4 %. At the initial evaluation, 62.0 % of the patients suffered from psychiatric comorbidity. Of the patients with initial comorbidity, 43.3 % were recovered at the one-year follow-up, compared to 62.8 % of the patients with no initial comorbidity, p=0.021.Conclusion: Our results confirm the previously known fact that psychiatric comorbidity among eating disorder patients is common. Also, the results identify psychiatric comorbidity as a possible factor to have negative effect on the treatment outcome.

Introdução: A esquizofrenia é um dos principais transtornos mentais e promove distúrbios comportamentais e cognitivos. Apesar do grande impacto social, pouco se conhece sobre a patofisiologia e etiologia da esquizofrenia. Pacientes com desordens psicóticas têm aumentado risco de desenvolver epilepsia, e pacientes com epilepsia do lobo temporal tem alta frequência de psicoses. A utilização de modelos experimentais animais de esquizofrenia e epilepsia pode ajudar a entender a neurobiologia dessas doenças e ter papel importante no desenvolvimento de novas estratégias terapêuticas. As interações complexas das crises epilépticas e quadros psicóticos tem sido aos poucos desvendadas. O óxido nítrico (NO) é um importante modulador da neurotransmissão e doadores de NO como o nitroprussiato de sódio (NPS) tem efeitos promissores em pacientes com esquizofrenia. Em modelos animais de epilepsia, NO pode ter efeito pró ou anticonvulsivante, sugerindo que o uso de NPS em pacientes com epilepsia e psicose pode não ser tão simples. Objetivos: Desenvolver um modelo animal de epilepsia e psicose comórbida, e compará-lo do ponto de vista comportamental e neuropatológico com modelos animais puros de epilepsia e esquizofrenia. Além disso, verificar a possível modulação desencadeada pelo tratamento com NPS nos modelos citados. Metodologia: Ratos Wistar machos (260-300g) foram divididos em grupos controle (SAL+SAL), epilepsia puro (PILO+SAL), esquizofrenia (SAL+QUET), epilepsia e psicose comórbida (PILO+QUET) e suas versões tratadas com NPS (SAL+SAL+NPS, PILO+SAL+NPS, SAL+QUET+NPS e PILO+QUET+NPS). Esses animais foram avaliados em diferentes aspectos comportamentais (campo aberto, teste de inibição pré- pulso, memória de reconhecimento de objeto e memória de trabalho), e filmados ao longo de 71 dias para o monitoramento de crises epilépticas espontâneas recorrentes. Também foram avaliadas a perda neuronal e a expressão de nNOS em diferentes regiões cerebrais. Resultados: NPS reduziu a frequência de crises nos animais com epilepsia e psicose comórbida quando comparados a animais não tratados. NPS também teve efeito ansiolítico no modelo animal de epilepsia com e sem psicose, e diminuiu os correlatos comportamentais de sintomas positivos dos animais no modelo de psicose e no de epilepsia + psicose, além de reverter o prejuízo no filtro sensório motor nos animais que receberam pilocarpina e quetamina. No reconhecimento de objeto o modelo de epilepsia e epilepsia+psicose o tratamento com NPS não interferiu no desempenho de memória de curto prazo, porém NPS melhorou a memória de longo prazo no modelo de psicose. NPS preservou regiões como o córtex entorrinal e subiculum nos animais epilépticos, mas a camada granular e córtex pré-límbico revelaram perda significativa nos animais controles. Alta expressão de nNOS em diferentes regiões cerebrais foram visualizadas nos animais com epilepsia, com destaque para aqueles que receberam tratamento com NPS. Conclusão: O tratamento com NPS foi efetivo na amenização de sintomas correlatos comportamentais de psicose no modelo puro de esquizofrenia e no comórbido VIII com epilepsia. Além disso, não exacerbou crises e contribuiu para diminuição delas nos animais do modelo de epilepsia e psicose, que apresentou grandes similaridades com o que é encontrado em casos clínicos. Nossos resultados sugerem que o uso do NPS pode ter resultados na melhoria dos sintomas da psicose interictal humana, assim como já observado para a esquizofrenia. / Introdution: Schizophrenia is a major mental disorder that affects 1% of young adults and has a great impact on quality of life, behavior, and cognition. Despite the high social burden, little is known about the pathophysiology and etiology of schizophrenia. Patients with psychotic disorders have increased risk of developing epilepsy, and patients with temporal lobe epilepsy have a high frequency of psychoses. The use of experimental animal models of epilepsy and schizophrenia may help to better understand the neurobiology of these diseases and play an important role in the development of potential new therapeutic strategies. The complex interactions of seizures and psychotic symptoms are being unveiled. Nitric oxide (NO) is an important modulator of neurotransmission and NO donors such as sodium nitroprusside (SNP) have shown promising effects in schizophrenic patients. In animal models of epilepsy, NO may exert pro- or anticonvulsant effects, suggesting that the use of SNP in patients with epilepsy and psychosis may not be so straightforward. Objectives: To develop an animal model of epilepsy and comorbid psychosis, and compare it from the behavioral and neuropathological point of view with pure animal models of epilepsy and schizophrenia. It was hoped, to verify the possible modulation triggered by the treatment with SNP. Metodology: Males Wistar rats weighing 260-300g were divided in controls group (SAL+SAL), pure epilepsy (PILO+SAL), schizophrenia (SAL+QUET), comorbid psychosis (PILO+KET) and their versions treated with SNP (SAL+SAL+SNP, PILO+SAL+SNP, SAL+KET+SNP and PILO+KET+SNP). These animals were evaluated in a variety of behavioral tests (open field, prepulse inhibition startle reflex, object recognition and working memory), and were filmed over 71 days to monitor spontaneous recurrent seizures. We also evaluated neuronal loss and nNOS expression in different brain regions. Results: SNP reduced seizure frequency in animals with epilepsy and psychosis when compared to those not treated with SNP. SNP also showed anxiolytic effects in the animal model of epilepsy with or without psychosis, decreased behavioral correlates of positive symptoms in the animal model of epilepsy + psychosis, and prevented sensorimotor gating deficits in epilepsy + psychosis IX model, The object recognition test showed that in epilepsy and epilepsy + psychosis models the treatment with SNP did not interfere with short-term memory performance, but SNP improved long-term memory in the psychosis model. SNP preserved brain regions like entorhinal cortex and subiculum in epileptic animals, but the granular layer and prelimbic cortex revealed significant loss in controls animals. High expression of NOS in same brain regions was observed in the animal model of epilepsy, especially in the animals receiving SNP. Conclusion: Treatment with SNP was effective in ameliorating symptoms of behavioral correlates of psychosis in the pure model of schizophrenia and the model comorbid with epilepsy. Moreover, SNP did not exacerbate seizures and reduced seizure frequency in the animal model of epilepsy + psychosis, which showed striking similarities to clinical cases. Our results suggest that the use of SNP could ameliorate symptoms of human interictal psychosis, such as those observed in schizophrenia.